All In Biotech

Drug Trial Radar · NCT07731919

Study on Doses of Inhaled ALX1 in Adults With Bronchiectasis

A Phase 2a, Placebo-Controlled, Single-Blind, Dose Range-Finding Study of Inhaled ALX1 in Adults With Bronchiectasis

Last checked: Nov 20, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

28

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Mar 31, 2027

Study completion Mar 31, 2027

Sponsor

Lead sponsor
Vast TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and effects of ALX1, an inhaled investigational treatment, in adults with bronchiectasis. Participants will receive either ALX1 or a placebo (a treatment with no active medicine) for 14 days. The study will compare different dose levels of ALX1 to help identify appropriate doses for future research based on safety, tolerability, and changes in predictive biomarkers.

Conditions

  • Bronchiectasis Adult

Interventions

  • ALX1Drug

    Dose Formulation: Solution for inhalation Dose Strength: 28 mg/mL Route of Administration: Inhalation via nebulizer

  • PlaceboDrug

    Dose Formulation: Solution for inhalation Dose Strength: 0.9% sodium chloride Route of Administration: Inhalation via nebulizer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with a metHb value ≥ 5% per dose levelTime frame: From Day 1 to Day 14 (EOT visit)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.